Terence R Flotte

List of Publications by Year
in descending order

136 papers	9,983 citations	36303 51 h-index	36028 97 g-index
140 all docs	140 docs citations	140 times ranked	6701 citing authors

#	Article	IF	Citations
1	Treatment of Leber Congenital Amaurosis Due toRPE65Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial. Human Gene Therapy, 2008, 19, 979-990.	2.7	880
2	Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 15112-15117.	7.1	639
3	Defective regulation of outwardly rectifying Clâ¯ channels by protein kinase A corrected by insertion of CFTR. Nature, 1992, 358, 581-584.	27.8	433
4	Mutational Analysis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Construction of AAV2 Vectors with Altered Tropism. Journal of Virology, 2000, 74, 8635-8647.	3.4	344
5	Phase 2 Clinical Trial of a Recombinant Adeno-Associated Viral Vector Expressing Î±₁-Antitrypsin: Interim Results. Human Gene Therapy, 2011, 22, 1239-1247.	2.7	297
6	Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 16363-16368.	7.1	295
7	A Phase I Study of an Adeno-Associated Virus-CFTR Gene Vector in Adult CF Patients with Mild Lung Disease. Johns Hopkins Children's Center, Baltimore, Maryland. Human Gene Therapy, 1996, 7, 1145-1159.	2.7	273
8	Î±-1 Antitrypsin Inhibits Caspase-3 Activity, Preventing Lung Endothelial Cell Apoptosis. American Journal of Pathology, 2006, 169, 1155-1166.	3.8	270
9	A Phase II, Double-Blind, Randomized, Placebo-Controlled Clinical Trial of tgAAVCF Using Maxillary Sinus Delivery in Patients with Cystic Fibrosis with Antrostomies. Human Gene Therapy, 2002, 13, 1349-1359.	2.7	239
10	Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet, The, 1998, 351, 1702-1703.	13.7	220
11	Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here?. Annual Review of Virology, 2019, 6, 601-621.	6.7	217
12	Phase I Trial of Intranasal and Endobronchial Administration of a Recombinant Adeno-Associated Virus Serotype 2 (rAAV2)-CFTR Vector in Adult Cystic Fibrosis Patients: A Two-Part Clinical Study. Human Gene Therapy, 2003, 14, 1079-1088.	2.7	213
13	Safety of Recombinant Adeno-Associated Virus Type 2â€“RPE65 Vector Delivered by Ocular Subretinal Injection. Molecular Therapy, 2006, 13, 1074-1084.	8.2	196
14	Safety and Biological Efficacy of an Adeno-Associated Virus Vector-Cystic Fibrosis Transmembrane Regulator (AAV-CFTR) in the Cystic Fibrosis Maxillary Sinus. Laryngoscope, 1999, 109, 266-274.	2.0	193
15	Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhoodâ€“Onset Retinal Dystrophy. Ophthalmology, 2016, 123, 1606-1620.	5.2	184
16	Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus Serotype 2Î±1-Antitrypsin (AAT) Vector in AAT-Deficient Adults. Human Gene Therapy, 2006, 17, 1177-1186.	2.7	168
17	Gene Expression from Adeno-associated Virus Vectors in Airway Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 1992, 7, 349-356.	2.9	167
18	CMV-Î²-Actin Promoter Directs Higher Expression from an Adeno-Associated Viral Vector in the Liver than the Cytomegalovirus or Elongation Factor 1Î± Promoter and Results in Therapeutic Levels of Human Factor X in Mice. Human Gene Therapy, 2001, 12, 563-573.	2.7	163

#	Article	IF	Citations
19	Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice. Nature Communications, 2021, 12, 2121.	12.8	155
20	Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy. Human Gene Therapy, 2020, 31, 695-696.	2.7	145
21	Latent Adeno-Associated Virus Infection Elicits Humoral but Not Cell-Mediated Immune Responses in a Nonhuman Primate Model. Journal of Virology, 1999, 73, 8549-8558.	3.4	143
22	Safety in Nonhuman Primates of Ocular AAV2-RPE65, a Candidate Treatment for Blindness in Leber Congenital Amaurosis. Human Gene Therapy, 2006, 17, 845-858.	2.7	142
23	Human Treg responses allow sustained recombinant adeno-associated virusâ€“mediated transgene expression. Journal of Clinical Investigation, 2013, 123, 5310-5318.	8.2	133
24	Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus Alpha 1-Antitrypsin (rAAV2-CB-hAAT) Gene Vector to AAT-Deficient Adults. Human Gene Therapy, 2004, 15, 93-128.	2.7	130
25	Lack of Cystic Fibrosis Transmembrane Conductance Regulator in CD3‹sup›+‹/sup›Lymphocytes Leads to Aberrant Cytokine Secretion and Hyperinflammatory Adaptive Immune Responses. American Journal of Respiratory Cell and Molecular Biology, 2011, 44, 922-929.	2.9	106
26	Gene therapy: The first two decades and the current state-of-the-art. Journal of Cellular Physiology, 2007, 213, 301-305.	4.1	105
27	Sustained miRNA-mediated Knockdown of Mutant AAT With Simultaneous Augmentation of Wild-type AAT Has Minimal Effect on Global Liver miRNA Profiles. Molecular Therapy, 2012, 20, 590-600.	8.2	105
28	A Phase I/II Study of tgAAV-CF for the Treatment of Chronic Sinusitis in Patients with Cystic Fibrosis. Stanford University, Stanford, California. Human Gene Therapy, 1998, 9, 889-909.	2.7	95
29	DNA-dependent PK inhibits adeno-associated virus DNA integration. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 2112-2116.	7.1	91
30	Immune Responses to Recombinant Adeno-Associated Virus Vectors: Putting Preclinical Findings into Perspective. Human Gene Therapy, 2004, 15, 716-717.	2.7	90
31	Repeated Delivery of Adeno-Associated Virus Vectors to the Rabbit Airway. Journal of Virology, 1999, 73, 9446-9455.	3.4	90
32	Intramuscular Administration of Recombinant Adeno-Associated Virus 2 Î±-1 Antitrypsin (rAAV-SERPINA1) Vectors in a Nonhuman Primate Model: Safety and Immunologic Aspects. Molecular Therapy, 2002, 6, 329-335.	8.2	87
33	Efficient Transduction of Vascular Endothelial Cells with Recombinant Adeno-Associated Virus Serotype 1 and 5 Vectors. Human Gene Therapy, 2005, 16, 235-247.	2.7	84
34	5 Year Expression and Neutrophil Defect Repair after Gene Therapy in Alpha-1 Antitrypsin Deficiency. Molecular Therapy, 2017, 25, 1387-1394.	8.2	84
35	A Single Intravenous rAAV Injection as Late as P20 Achieves Efficacious and Sustained CNS Gene Therapy in Canavan Mice. Molecular Therapy, 2013, 21, 2136-2147.	8.2	77
36	Efficient and Targeted Transduction of Nonhuman Primate Liver With Systemically Delivered Optimized AAV3B Vectors. Molecular Therapy, 2015, 23, 1867-1876.	8.2	73

#	Article	IF	Citations
37	Histone Deacetylase Inhibitor (HDACi) Suberoylanilide Hydroxamic Acid (SAHA)-mediated Correction of Î±1-Antitrypsin Deficiency. Journal of Biological Chemistry, 2012, 287, 38265-38278.	3.4	72
38	Adeno-Associated Virus Type 2 and Hepatocellular Carcinoma?. Human Gene Therapy, 2015, 26, 779-781.	2.7	71
39	Viral Vectorâ€“mediated and Cell-based Therapies for Treatment of Cystic Fibrosis. Molecular Therapy, 2007, 15, 229-241.	8.2	67
40	Therapeutic level of functional human alpha 1 antitrypsin (hAAT) secreted from murine muscle transduced by adenoâ€associated virus (rAAV1) vector. Journal of Gene Medicine, 2006, 8, 730-735.	2.8	62
41	Survival Advantage of Both Human Hepatocyte Xenografts and Genome-Edited Hepatocytes for Treatment of Î±-1 Antitrypsin Deficiency. Molecular Therapy, 2017, 25, 2477-2489.	8.2	62
42	Editing out five Serpina1 paralogs to create a mouse model of genetic emphysema. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2788-2793.	7.1	62
43	Production of clinical-grade recombinant adeno-associated virus vectors. Current Opinion in Biotechnology, 2002, 13, 418-423.	6.6	61
44	Adeno-Associated Virus: A Ubiquitous Commensal of Mammals. Human Gene Therapy, 2005, 16, 401-407.	2.7	60
45	Alternate Translation Initiation Codons Can Create Functional Forms of Cystic Fibrosis Transmembrane Conductance Regulator. Journal of Biological Chemistry, 1995, 270, 11941-11946.	3.4	58
46	Preclinical Evaluation of a Recombinant Adeno-Associated Virus Vector Expressing Human Alpha-1 Antitrypsin Made Using a Recombinant Herpes Simplex Virus Production Method. Human Gene Therapy, 2011, 22, 155-165.	2.7	58
47	A Safe and Reliable Technique for CNS Delivery of AAV Vectors in the Cisterna Magna. Molecular Therapy, 2020, 28, 411-421.	8.2	58
48	Functional Characterization of a Recombinant Adeno- Associated Virus 5-Pseudotyped Cystic Fibrosis Transmembrane Conductance Regulator Vector. Human Gene Therapy, 2004, 15, 832-841.	2.7	57
49	In vivo post-transcriptional gene silencing of Î±-1 antitrypsin by adeno-associated virus vectors expressing siRNA. Laboratory Investigation, 2007, 87, 893-902.	3.7	57
50	In VivoGenome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency. Human Gene Therapy, 2018, 29, 853-860.	2.7	54
51	Recent Developments in Recombinant AAV-Mediated Gene Therapy for Lung Diseases. Current Gene Therapy, 2005, 5, 361-366.	2.0	53
52	Efficient Hepatic Delivery and Expression from a Recombinant Adeno-associated Virus 8 Pseudotyped Î±1-Antitrypsin Vector. Molecular Therapy, 2005, 12, 867-875.	8.2	53
53	Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for Î±-1-antitrypsin deficiency. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1655-1659.	7.1	52
54	Dual Reporter Comparative Indexing of rAAV Pseudotyped Vectors in Chimpanzee Airway. Molecular Therapy, 2010, 18, 594-600.	8.2	49

#	Article	IF	Citations
55	AAV gene therapy for Tay-Sachs disease. Nature Medicine, 2022, 28, 251-259.	30.7	49
56	Expression of a Truncated Cystic Fibrosis Transmembrane Conductance Regulator with an AAV5-pseudotyped Vector in Primates. Molecular Therapy, 2007, 15, 756-763.	8.2	48
57	Preclinical Characterization of A Recombinant Adeno-Associated Virus Type 1-Pseudotyped Vector Demonstrates Dose-Dependent Injection Site Inflammation And Dissemination of Vector Genomes to Distant Sites. Human Gene Therapy, 2007, 18, 245-256.	2.7	48
58	Gene Therapy for Cystic Fibrosis. Clinical Reviews in Allergy and Immunology, 2008, 35, 164-178.	6.5	48
59	Recombinant AAV Serotype and Capsid Mutant Comparison for Pulmonary Gene Transfer of Î±-1-Antitrypsin Using Invasive and Noninvasive Delivery. Molecular Therapy, 2009, 17, 81-87.	8.2	48
60	Results at 5 Years After Gene Therapy for RPE65-Deficient Retinal Dystrophy. Human Gene Therapy, 2018, 29, 1428-1437.	2.7	48
61	Gene-Based Therapy for Alpha-1 Antitrypsin Deficiency. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2013, 10, 44-49.	1.6	47
62	Adeno-Associated Virus-Based Gene Therapy for Inherited Disorders. Pediatric Research, 2005, 58, 1143-1147.	2.3	45
63	CAR T-Cell Therapy: Progress and Prospects. Human Gene Therapy Methods, 2017, 28, 61-66.	2.1	45
64	Gene therapy for alpha-1 antitrypsin deficiency. Human Molecular Genetics, 2011, 20, R87-R92.	2.9	43
65	Effect of Cigarette Smoke Exposure and Structural Modifications on the Î±-1 Antitrypsin Interaction with Caspases. Molecular Medicine, 2012, 18, 445-454.	4.4	43
66	Successful transgene expression with serial doses of aerosolized rAAV2 vectors in rhesus macaques. Molecular Therapy, 2003, 8, 918-926.	8.2	42
67	A Rationally Engineered Capsid Variant of AAV9 for Systemic CNS-Directed and Peripheral Tissue-Detargeted Gene Delivery in Neonates. Molecular Therapy - Methods and Clinical Development, 2018, 9, 234-246.	4.1	42
68	Accelerated Graduation and the Deployment of New Physicians During the COVID-19 Pandemic. Academic Medicine, 2020, 95, 1492-1494.	1.6	41
69	Functional Characterization of a Recombinant Adeno-Associated Virus 5-Pseudotyped Cystic Fibrosis Transmembrane Conductance Regulator Vector. Human Gene Therapy, 2004, 15, 832-841.	2.7	41
70	Recombinant Adeno-Associated Virus Integration Sites in Murine Liver After Ornithine Transcarbamylase Gene Correction. Human Gene Therapy, 2013, 24, 520-525.	2.7	40
71	Adeno-Associated Virus Neutralizing Antibodies in Large Animals and Their Impact on Brain Intraparenchymal Gene Transfer. Molecular Therapy - Methods and Clinical Development, 2018, 11, 65-72.	4.1	38
72	Ex Vivo transduced liver progenitor cells as a platform for gene therapy in mice. Hepatology, 2004, 40, 918-924.	7.3	37

#	Article	IF	Citations
73	Recombinant Adeno-Associated Virus-Mediated Global Anterograde Delivery of Glial Cell Line-Derived Neurotrophic Factor to the Spinal Cord: Comparison of Rubrospinal and Corticospinal Tracts in the Rat. Human Gene Therapy, 2008, 19, 71-82.	2.7	36
74	Correlation Between DNA Transfer and Cystic Fibrosis Airway Epithelial Cell Correction After Recombinant Adeno-Associated Virus Serotype 2 Gene Therapy. Human Gene Therapy, 2005, 16, 921-928.	2.7	35
75	Delayed Expression of Adeno-Associated Virus Vector DNA. Intervirology, 1999, 42, 213-220.	2.8	33
76	Recombinant Adeno-Associated Virus Vector-Based Gene Transfer for Defects in Oxidative Metabolism. Human Gene Therapy, 2000, 11, 2067-2078.	2.7	33
77	Cystic Fibrosis Transmembrane Regulator Missing the First Four Transmembrane Segments Increases Wild Type and Î”F508 Processing*. Journal of Biological Chemistry, 2008, 283, 21926-21933.	3.4	33
78	The rapidly evolving state of gene therapy. FASEB Journal, 2018, 32, 1733-1740.	0.5	33
79	Localized Gene Expression Following Administration of Adeno-associated Viral Vectors via Pancreatic Ducts. Molecular Therapy, 2005, 12, 519-527.	8.2	30
80	Enhanced IgE allergic response to Aspergillus fumigatus in CFTRâˆ’/âˆ’ mice. Laboratory Investigation, 2006, 86, 130-140.	3.7	29
81	Partial correction of the CFTRâ€dependent ABPA mouse model with recombinant adenoâ€associated virus gene transfer of truncated CFTR gene. Journal of Gene Medicine, 2008, 10, 51-60.	2.8	29
82	Current status of gene therapy for Î±-1 antitrypsin deficiency. Expert Opinion on Biological Therapy, 2015, 15, 329-336.	3.1	29
83	CRISPR/Cas-Dependent and Nuclease-FreeIn VivoTherapeutic Gene Editing. Human Gene Therapy, 2021, 32, 275-293.	2.7	26
84	[53] Adeno-associated virus vectors for gene therapy of cystic fibrosis. Methods in Enzymology, 1998, 292, 717-732.	1.0	24
85	Muscle-Directed Delivery of an AAV1 Vector Leads to Capsid-Specific T Cell Exhaustion in Nonhuman Primates and Humans. Molecular Therapy, 2020, 28, 747-757.	8.2	23
86	Recombinant Adeno-Associated Virus Gene Therapy for Cystic Fibrosis and Î±1-Antitrypsin Deficiency. Chest, 2002, 121, 98S-102S.	0.8	21
87	Long-term Correction of Very Long-chain Acyl-CoA Dehydrogenase Deficiency in Mice Using AAV9 Gene Therapy. Molecular Therapy, 2012, 20, 1131-1138.	8.2	20
88	Development of rAAV2-CFTR: History of the First rAAV Vector Product to be Used in Humans. Human Gene Therapy Methods, 2016, 27, 49-58.	2.1	19
89	Recombinant Adeno-Associated Virus Vector Genomes Take the Form of Long-Lived, Transcriptionally Competent Episomes in Human Muscle. Human Gene Therapy, 2016, 27, 32-42.	2.7	18
90	Systemic Correction of a Fatty Acid Oxidation Defect by Intramuscular Injection of a Recombinant Adeno-Associated Virus Vector. Human Gene Therapy, 2006, 17, 71-80.	2.7	17

#	Article	IF	Citations
91	Cell and Gene Therapy for Genetic Diseases: Inherited Disorders Affecting the Lung and Those Mimicking Sudden Infant Death Syndrome. Human Gene Therapy, 2012, 23, 548-556.	2.7	17
92	Birth of a New Therapeutic Platform: 47 Years of Adeno-associated Virus Biology From Virus Discovery to Licensed Gene Therapy. Molecular Therapy, 2013, 21, 1976-1981.	8.2	16
93	Modulating Immune Responses to AAV by expanded polyclonal T-regulatory cells and capsid specific chimeric antigen receptor T-regulatory cells. Molecular Therapy - Methods and Clinical Development, 2021, 23, 490-506.	4.1	16
94	CFTR mutations impart elevated immune reactivity in a murine model of cystic fibrosis related diabetes. Cytokine, 2008, 44, 154-159.	3.2	15
95	Adeno-Associated Virus-Mediated Gene Transfer for Lung Diseases. Human Gene Therapy, 2005, 16, 643-648.	2.7	13
96	Gene Transfer in the Lung Using Recombinant Adenoâ€Associated Virus. Current Protocols in Microbiology, 2012, 26, Unit14D.2.	6.5	13
97	Progress with Recombinant Adeno-Associated Virus Vectors for Gene Therapy of Alpha-1 Antitrypsin Deficiency. Human Gene Therapy Methods, 2015, 26, 77-81.	2.1	12
98	Retro-Orbital Venous Sinus Delivery of rAAV9 Mediates High-Level Transduction of Brain and Retina Compared with Temporal Vein Delivery in Neonatal Mouse Pups. Human Gene Therapy, 2017, 28, 228-230.	2.7	12
99	Two-Plasmid Packaging System for Recombinant Adeno-Associated Virus. BioResearch Open Access, 2020, 9, 219-228.	2.6	12
100	Common pathways to Dean of Medicine at U.S. medical schools. PLoS ONE, 2021, 16, e0249078.	2.5	12
101	Real time laryngoscopy with olfactory challenge for diagnosis of psychogenic stridor. Pediatric Pulmonology, 1993, 16, 259-262.	2.0	10
102	Biochemical Correction of Short-Chain Acyl-Coenzyme A Dehydrogenase Deficiency After Portal Vein Injection of rAAV8-SCAD. Human Gene Therapy, 2008, 19, 579-588.	2.7	10
103	Charting a Clear Path: The ASGCT Standardized Pathways Conference. Molecular Therapy, 2014, 22, 1235-1238.	8.2	10
104	Bridging from Intramuscular to Limb Perfusion Delivery of rAAV: Optimization in a Non-human Primate Study. Molecular Therapy - Methods and Clinical Development, 2019, 13, 233-242.	4.1	10
105	Recent developments in the protection of pediatric research subjects. Journal of Pediatrics, 2006, 149, 285-286.e2.	1.8	9
106	Therapeutics: Gene Therapy for Alpha-1 Antitrypsin Deficiency. Methods in Molecular Biology, 2017, 1639, 267-275.	0.9	9
107	Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies. Pharmacogenomics, 2008, 9, 947-968.	1.3	8
108	N-Glycosylation Augmentation of the Cystic Fibrosis Epithelium Improves Pseudomonas aeruginosa Clearance. American Journal of Respiratory Cell and Molecular Biology, 2011, 44, 824-830.	2.9	8

#	Article	IF	Citations
109	Recombinant adenoâ€associated virusâ€mediated gene delivery of long chain acyl coenzyme A dehydrogenase (LCAD) into LCADâ€deficient mice. Journal of Gene Medicine, 2008, 10, 1113-1123.	2.8	7
110	Apparently Nonspecific Enzyme Elevations After Portal Vein Delivery of Recombinant Adeno-Associated Virus Serotype 2 Vector in Hepatitis C Virus-Infected Chimpanzees. Human Gene Therapy, 2008, 19, 681-689.	2.7	7
111	Modulation of Exaggerated-IgE Allergic Responses by Gene Transfer-mediated Antagonism of IL-13 and IL-17e. Molecular Therapy, 2010, 18, 511-518.	8.2	7
112	Large-scale molecular epidemiological analysis of AAV in a cancer patient population. Oncogene, 2021, 40, 3060-3071.	5.9	7
113	Gene Therapy for Rare Neurological Disorders. Clinical Pharmacology and Therapeutics, 2022, 111, 743-757.	4.7	7
114	Recombinant Adeno-Associated Virus-Mediated Gene Transfer for the Potential Therapy of Adenosine Deaminase-Deficient Severe Combined Immune Deficiency. Human Gene Therapy, 2011, 22, 935-949.	2.7	6
115	Ethical Implications of the Cost of Molecularly Targeted Therapies. Human Gene Therapy, 2015, 26, 573-574.	2.7	6
116	InÂvivo gene editing works in humans: Results of a phase 1 clinical trial for TTR amyloidosis. Molecular Therapy, 2021, 29, 2633-2634.	8.2	6
117	AAV9 gene replacement therapy for respiratory insufficiency in veryâ€long chain acylâ€CoA dehydrogenase deficiency. Journal of Inherited Metabolic Disease, 2019, 42, 870-877.	3.6	5
118	Volume and Infusion Rate Dynamics of Intraparenchymal Central Nervous System Infusion in a Large Animal Model. Human Gene Therapy, 2020, 31, 617-625.	2.7	5
119	Liver-directed SERPINA1 gene therapy attenuates progression of spontaneous and tobacco smoke-induced emphysema in Î±1-antitrypsin null mice. Molecular Therapy - Methods and Clinical Development, 2022, 25, 425-438.	4.1	5
120	Delivery of Adeno-Associated Virus Gene Therapy by Intravascular Limb Infusion Methods. Human Gene Therapy Clinical Development, 2015, 26, 159-164.	3.1	4
121	Engraftment of Human Hepatocytes in the PiZ-NSG Mouse Model. Methods in Molecular Biology, 2020, 2164, 75-85.	0.9	4
122	Preclinical Study Design for rAAV. Methods in Molecular Biology, 2012, 807, 317-337.	0.9	3
123	What Is Suppression of Antiâ€“Adeno-Associated Virus Capsid T-Cells Achieving?. Human Gene Therapy, 2014, 25, 178-179.	2.7	3
124	Supporting Families Considering Participation in a Clinical Trial: Parent-Provider Perspectives. Pediatrics, 2021, 147, .	2.1	3
125	Adeno-Associated Viral Vectors for CF Gene Therapy. , 2002, 70, 599-608.		2
126	Moving Forward Toward a Cure for Parkinson's: Neuropathology of the Nigrostriatal Pathway Determines the Location of Growth Factor Delivery. Molecular Therapy, 2011, 19, 827-829.	8.2	2

#	Article	IF	Citations
127	Quantification of Total Human Alpha-1 Antitrypsin by Sandwich ELISA. Methods in Molecular Biology, 2017, 1639, 211-216.	0.9	2
128	The Gene Therapy Resource Program: A Decade of Dedication to Translational Research by the National Heart, Lung, and Blood Institute. Human Gene Therapy Clinical Development, 2017, 28, 178-186.	3.1	2
129	DNA Vaccination in 2018: An Update. Human Gene Therapy, 2018, 29, 963-965.	2.7	1
130	The signal and the trap: Targeted delivery and retention of proteins in the mitochondrion. Molecular Therapy, 2003, 7, 715-716.	8.2	0
131	In Utero Efficacy of Cystic Fibrosis Gene Therapy: Difficult Studies, Positive or Negative. Molecular Therapy, 2008, 16, 806-807.	8.2	0
132	Getting Tough on Capsid Screening: Tough Decoys Enable Barcoding of Vectors Capable of both Entry and Expression. Human Gene Therapy, 2019, 30, 919-920.	2.7	0
133	Gene and Cell Therapy for Inherited and Acquired Immune Deficiency. Human Gene Therapy, 2021, 32, 1-3.	2.7	0
134	Liver targeting with rAAV7: balancing tropism with immune profiles. Gene Therapy, 2021, 28, 115-116.	4.5	0
135	In Reply to Ramotshwana et al. Academic Medicine, 2021, 96, e15-e16.	1.6	0
136	Muscle-Directed Gene Therapy for Alpha-1 Antitrypsin Deficiency. , 2019, , 775-786.		0